13 recruiting, 6 active not recruiting, 4 completed, 3 terminated. 16 Phase 2, 12 Phase 1, 6 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Stage IV Hepatocellular Carcinoma AJCC v8: new trials by email Literature Review of Stage IV Hepatocellular Carcinoma AJCC v8 trials Research Report on Stage IV Hepatocellular Carcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis | Phase 1 / Phase 2 | Recruiting | Devalingam Mahalingam | 59 | 2026-03-30 | 2026-06-25 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 92 | 2025-11-17 | 2026-10-16 |
| AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma | Phase 1 | Suspended | University of Southern California | 36 | 2023-03-29 | 2026-08-17 |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Atezolizumab, Cabozantinib, Lenvatinib - Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 122 | 2022-05-27 | 2026-08-04 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant Laboratory Biomarker Analysis, Lenvatinib - Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Terminated | Emory University | 3 | 2022-04-19 | 2026-04-24 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Recruiting | Mary Feng, MD | 21 | 2022-02-04 | 2025-12-08 |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Completed | Mayo Clinic | 26 | 2022-01-30 | 2026-09-29 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Durvalumab, Tremelimumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 25 | 2021-08-03 | 2026-04-20 |
| Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events Best Practice, Patient Monitoring, Questionnaire Administration - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 750 | 2021-05-12 | 2026-06-16 |
| Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2021-01-13 | 2026-09-14 |
Showing 20 of 30. Sign in to see all of them.
Carcinoma, Hepatocellular (30) · Carcinoma, Renal Cell (4) · Melanoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Cholangiocarcinoma (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Ovarian Neoplasms (2)
Adenocarcinoma (30) · Carcinoma (30) · Digestive System Diseases (30) · Digestive System Neoplasms (30) · Liver Diseases (30) · Liver Neoplasms (30) · Neoplasms (30) · Neoplasms by Histologic Type (30) · Neoplasms by Site (30) · Neoplasms, Glandular and Epithelial (30) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Breast Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4)
Magnetic Resonance Spectroscopy (12) · Specimen Handling (12) · Immunoglobulin G (7) · Nivolumab (7) · Disulfides (6) · durvalumab (6) · tremelimumab (5) · Biopsy (4) · X-Rays (4) · atezolizumab (4) · cabozantinib (4) · Cyclophosphamide (3) · Bevacizumab (2) · CTLA-4 Antigen (2) · Ipilimumab (2)
M.D. Anderson Cancer Center (6) · Mayo Clinic (4) · National Cancer Institute (NCI) (3) · Academic and Community Cancer Research United (2) · City of Hope Medical Center (2) · Emory University (2) · OHSU Knight Cancer Institute (2) · University of Southern California (2) · Devalingam Mahalingam (1) · Edward Kim (1) · Mary Feng, MD (1) · NRG Oncology (1) · Robin Kate Kelley (1) · Roswell Park Cancer Institute (1) · University of California, San Francisco (1)
United States (30) · Canada (1)
Armeen Mahvash (2) · Daneng Li (2) · Mary Feng, MD (2) · Adel Kardosh (1) · Anthony B El-Khoueiry, MD (1) · Anuradha Krishnamurthy (1) · Anwaar Saeed (1) · Apostolia M Tsimberidou (1) · Devalingam Mahalingam (1) · Diana Hanna (1) · Dustin A Deming (1) · Edward Kim, MD, PhD (1) · Emmanuel M Gabriel, M.D., Ph.D. (1) · Haiying Cheng (1) · Jennifer Y Wo (1)
PMID 12001988, PMID 17704903, PMID 19906081, PMID 19917863, PMID 20061178, PMID 20233873, PMID 20336386, PMID 20374484, PMID 20490982, PMID 20737573, PMID 21153378, PMID 21909917, PMID 21926464, PMID 22162570, PMID 23456602, PMID 24956510, PMID 25013744, PMID 26883450, PMID 2801858, PMID 33654117, PMID 34272087, PMID 36821818, PMID 37124504, PMID 3808620, PMID 39932259, PMID 41831609, PMID 42847673
P30CA014089 (2), P30CA015083 (2), P30CA016672 (2), P30CA033572 (2), P30CA138292 (2), P30CA060553 (1), P30CA093373 (1), R01CA274985 (1), R01CA294704 (1), U10CA180820 (1), U10CA180868 (1), UM1CA186690 (1)